MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461708 | Name: Saintopin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Saintopin is an anticancer agent that induces DNA cleavage mediated by both topoisomerase (topo) I and topo II in vitro through stabilization of the reversible enzyme-DNA cleavable complex.

Chemical Structure

Saintopin
Saintopin
CAS#131190-63-1

Theoretical Analysis

MedKoo Cat#: 461708

Name: Saintopin

CAS#: 131190-63-1

Chemical Formula: C18H10O7

Exact Mass: 338.0427

Molecular Weight: 338.27

Elemental Analysis: C, 63.91; H, 2.98; O, 33.11

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Saintopin;
IUPAC/Chemical Name
1,3,8,10,11-pentahydroxytetracene-5,12-dione
InChi Key
CGFVUVWMYIHGHS-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H10O7/c19-7-1-6-2-9-15(17(24)13(6)11(21)4-7)18(25)14-10(16(9)23)3-8(20)5-12(14)22/h1-5,19-22,24H
SMILES Code
O=C(C1=C2C(O)=C3C(O)=CC(O)=CC3=C1)C4=CC(O)=CC(O)=C4C2=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 338.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Fujii N, Yamashita Y, Mizukami T, Nakano H. Correlation between the formation of cleavable complex with topoisomerase I and growth-inhibitory activity for saintopin-type antibiotics. Mol Pharmacol. 1997 Feb;51(2):269-76. PubMed PMID: 9203632. 2: Taniguchi K, Kohno K, Kawanami K, Wada M, Kanematsu T, Kuwano M. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res. 1996 May 15;56(10):2348-54. PubMed PMID: 8625310. 3: Martin P, Rodier S, Mondon M, Renoux B, Pfeiffer B, Renard P, Pierré A, Gesson JP. Synthesis and cytotoxic activity of tetracenomycin D and of saintopin analogues. Bioorg Med Chem. 2002 Feb;10(2):253-60. PubMed PMID: 11741773. 4: Yamashita Y, Kawada S, Fujii N, Nakano H. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry. 1991 Jun 18;30(24):5838-45. PubMed PMID: 1646001. 5: Ishiyama D, Futamata K, Futamata M, Kasuya O, Kamo S, Yamashita F, Kanazawa S. Novel selective inhibitors for human topoisomerase I, BM2419-1 and -2 derived from saintopin. J Antibiot (Tokyo). 1998 Dec;51(12):1069-74. PubMed PMID: 10048564. 6: Leteurtre F, Fujimori A, Tanizawa A, Chhabra A, Mazumder A, Kohlhagen G, Nakano H, Pommier Y. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem. 1994 Nov 18;269(46):28702-7. PubMed PMID: 7961822. 7: Yamashita Y, Saitoh Y, Ando K, Takahashi K, Ohno H, Nakano H. Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilomyces. J Antibiot (Tokyo). 1990 Oct;43(10):1344-6. PubMed PMID: 2175304. 8: Knab AM, Fertala J, Bjornsti MA. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons. J Biol Chem. 1995 Mar 17;270(11):6141-8. PubMed PMID: 7890748. 9: Verma RP. Anti-cancer activities of 1,4-naphthoquinones: a QSAR study. Anticancer Agents Med Chem. 2006 Sep;6(5):489-99. Review. PubMed PMID: 17017857. 10: Pommier Y, Jenkins J, Kohlhagen G, Leteurtre F. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. Mutat Res. 1995 Sep;337(2):135-45. PubMed PMID: 7565862. 11: Kim BH, Yoo J, Park SH, Jung JK, Cho H, Chung Y. Synthesis and evaluation of antitumor activity of novel 1,4-naphthoquinone derivatives (IV). Arch Pharm Res. 2006 Feb;29(2):123-30. PubMed PMID: 16526275. 12: Kohlhagen G, Paull KD, Cushman M, Nagafuji P, Pommier Y. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol Pharmacol. 1998 Jul;54(1):50-8. PubMed PMID: 9658189.

View History

Safotibant

Safotibant

RS 5773

RS 5773

NSC145366

NSC145366

RS-56812 hydrochloride

RS-56812 hydrochloride

GBR-12966

GBR-12966

KHN62738

KHN62738